- |||||||||| CDR101 - CDR / Life
Preclinical Assessment of CDR101 – a BCMAxCD3xPD-L1 Trispecific Antibody with Superior Anti-Tumor Efficacy (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_3162;
In contrast to high-affinity PD-L1 immune checkpoint inhibitors, CDR101 selectively inhibits PD-L1 at the immune synapse preventing on-target off-tumor effects. This is expected to translate into a decreased incidence of immune related adverse events (irAEs) and better efficacy arguing for a high clinical potential and swift translation into the clinic.
|
